Inhibition of poly(ADP-ribose) polymerase in cancer.
Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.
Plummer
Elizabeth Ruth
ER
Northern Institute for Cancer Research, Paul O'Gorman Building, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. e.r.plummer@ncl.ac.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000532:radiotherapy; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases